Supplements vergleichen

Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.

Any time

Subkutaner Einmal-wöchentlich-Pen (Trulicity)

Investigational / China-only dosing: once-weekly subcutaneous injection, dose-escalated over several weeks. Trial maintenance doses studied were 4 mg, 6 mg, and 9 mg once weekly (lower doses used during titration to limit GI effects). There is no FDA-approved regimen.

Any time

Einmal wöchentliche subkutane Injektion (in Erprobung; in China als Xinermei zugelassen)

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior serious hypersensitivity to dulaglutide or any GLP-1 receptor agonist

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists

• Pregnancy and breastfeeding
• Personal or family history of medullary thyroid carcinoma or MEN2 (class-level precaution for GLP-1-based agents)
• History of pancreatitis (use with caution / avoid)

• Insulin and sulfonylureas
• Oral medications generally